BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Dow
Novartis
Accenture
Baxter
Argus Health
Boehringer Ingelheim
McKinsey
Moodys
Fuji

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,658,663

« Back to Dashboard

Summary for Patent: 8,658,663
Title:Method of treating thermoregulatory disfunction with paroxetine
Abstract: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.
Inventor(s): Richards; Patricia Allison Tewes (Scarsdale, NY)
Assignee: Noven Therapeutics, LLC (Miami, FL)
Application Number:12/292,960
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,658,663

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,658,663

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,576 Method of treating thermoregulatory dysfunction with paroxetine ➤ Subscribe
8,946,251 Method of treating thermoregulatory dysfunction with paroxetine ➤ Subscribe
9,393,237 Method of treating thermoregulatory dysfunction with paroxetine ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,658,663

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007282065 ➤ Subscribe
Brazil PI0715087 ➤ Subscribe
Canada 2659577 ➤ Subscribe
China 101505759 ➤ Subscribe
European Patent Office 2068881 ➤ Subscribe
European Patent Office 2719385 ➤ Subscribe
Israel 196844 ➤ Subscribe
Japan 2009545593 ➤ Subscribe
Japan 2014077023 ➤ Subscribe
Japan 5846717 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Queensland Health
Cantor Fitzgerald
Baxter
QuintilesIMS
Dow
UBS
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot